SCHEMBL20124833

SCHEMBL20124833

Cc1cnn(-c2ccc(C(F)(F)F)cn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 3/20 0.47
APAF1 O14727 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HDAC4 P56524 1/20 0.46
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
FAAH O00519 1/20 0.42
HPGD P15428 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26422895 0.83 HDAC4 (0.46) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL22925831 0.81 HDAC4 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL29620876 0.81 HDAC4 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL22925947 0.81 HDAC4 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL29620920 0.81 HDAC4 (0.49) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL12498160 0.81 HDAC4 (0.46) MAPTSMN1; SMN2KDM4EALDH1A1APAF1
SCHEMBL16547509 0.79 ALDH1A1 (0.44) MAPTSMN1; SMN2KDM4EALDH1A1L3MBTL1
SCHEMBL27133083 0.78 ADRB1 (0.46) MAPTKDM4EALDH1A1MEN1CYP1A2
SCHEMBL27496862 0.78 NOTUM (0.44) MAPTSMN1; SMN2KDM4EALDH1A1TDP1
SCHEMBL27915290 0.77 EGLN1 (0.55) HDAC4MEN1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023128786-A1 NEW ANTIVIRAL TRIAZOLE DERIVATIVES, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN VIRAL INFECTIONS COLLABORATIONS PHARMACEUTICALS, INC (US) 2023-07-06 WO disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB MAPT 2083/4885SMN1; SMN2 863/4885KDM4E 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.